150
Views
3
CrossRef citations to date
0
Altmetric
Case Reports

Management of Inflammatory Choroidal Neovascularization (CNV) Secondary to Punctate Inner Choroidopathy in a Young Female of Childbearing Age with Intra-vitreal Ranibizumab and Half-fluence Photodynamic Therapy (PDT) − A Holistic Approach

, &
Pages 29-32 | Received 06 Mar 2011, Accepted 21 Jul 2011, Published online: 21 Feb 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Kirill Zaslavsky, Teresa Park, Rachel Lang Mcinnis, Mark Mandell, Jihwan Lee, Christopher Lee, Rose Gilbert & Larissa Derzko-Dzulynsky. (2023) Outcomes in PIC-Related CNV: Pooled Analysis of Individual Participant Data. Ocular Immunology and Inflammation 31:9, pages 1825-1836.
Read now
Petros Petrou, Ilias Georgalas, Nikolaos Markomichelakis, Ioannis Vergados, Emanuela Gianakaki & Alexander Rouvas. (2013) Resolution of vitreomacular traction following intravitreal ranibizumab in cases of ocular toxoplasmosis with choroidal neovascularization. Therapeutics and Clinical Risk Management 9, pages 391-394.
Read now

Articles from other publishers (1)

Hyun Woong KimYong Wun ChoIn Young Chung. (2016) Management of Relapsed Inflammatory Choroidal Neovascularization in Punctate Inner Choroidopathy after Bevacizumab. Journal of the Korean Ophthalmological Society 57:3, pages 513.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.